Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05822752 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 2 study of Hepatocellular Carcinoma, sponsored by AbbVie.
- Active
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT05822752 is a Phase 2 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 130 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05822752, a Phase 2 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), lenvatinib, or sorafenib. Approximately 120 adult participants will be enrolled in the study across 60 sites worldwide. In arm 1 (control), participants will receive the investigator's choice: lenvatinib as an oral capsule or sorafenib as an oral tablet, once daily. In arm 2, participants will receive intravenously (IV) infused livmoniplimab (dose A) in combination with IV infused budigalimab, every 3 weeks. In arm 3, participants will receive intravenously (IV) infused livmoniplimab (dose B) in combination with IV infused budigalimab, every 3 weeks. The estimated duration of the study is up to 2 years There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Conditions Studied
Interventions
- DRUG Budigalimab
- DRUG Lenvatinib
- DRUG Sorafenib
- DRUG Livmoniplimab
Study Locations (20)
California
- University of California, Los Angeles /ID# 253292 - Los Angeles
- UC Irvine /ID# 252707 - Orange
- California Pacific Medical Center - San Francisco - Webster Street /ID# 253291 - San Francisco
Texas
- Duplicate_Texas Oncology - Medical City Dallas /ID# 254164 - Dallas
- Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 252770 - Dallas
- Texas Oncology - Northeast Texas /ID# 254184 - Tyler
New York
- NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 252708 - New York
- Memorial Sloan Kettering Cancer Center-Koch Center /ID# 252705 - New York
North Carolina
- Messino Cancer Center - Asheville /ID# 253888 - Asheville
- University of North Carolina /ID# 252739 - Chapel Hill
Arizona
- Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313 - Prescott Valley
Arkansas
- Highlands Oncology Group, PA /ID# 253158 - Springdale
Colorado
- Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163 - Denver
Florida
- AdventHealth Orlando /ID# 252865 - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05822752
The ClinicalTrials.gov registry entry for NCT05822752 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (49% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Budigalimab is the first listed.
NCT05822752 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Texas, New York.
Frequently Asked Questions
What is clinical trial NCT05822752 about?
NCT05822752 is a clinical study titled "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)". Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy ...
What is the current status of trial NCT05822752?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2023-09-21. Estimated completion is 2026-11.
What conditions does trial NCT05822752 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05822752?
The interventions under investigation include: Budigalimab (DRUG), Lenvatinib (DRUG), Sorafenib (DRUG), Livmoniplimab (DRUG).
Who is sponsoring clinical trial NCT05822752?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05822752 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.